<DOC>
	<DOC>NCT00931372</DOC>
	<brief_summary>The objective of this study is to test whether Lixisenatide (AVE0010) restores first phase and improves second phase insulin response in subjects with diabetes mellitus type 2.</brief_summary>
	<brief_title>Lixisenatide for Restoration of Insulin Release in Subjects With Diabetes Mellitus Type 2</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Male and female subjects with type 2 diabetes mellitus on diet and exercise with/without metformin HbA1c&gt;=6,0 % and &lt;=8,5 % at screening BMI 25 to 35 kg/mÂ² 155&gt;=BP systolic &gt;=90 mmHg 100&gt;=BP diastolic&gt;=45 mmHg The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Insulin release</keyword>
	<keyword>Diabetes mellitus type 2</keyword>
	<keyword>GLP-1 agonist</keyword>
</DOC>